Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Mabwell Announces the NMPA Approval of Novel Trop-2 ADC (9MW2921)

Wednesday, July 19, 2023

Mabwell has announced the approval of clinical trial application for 9MW2921 by the National Medical Products Administration (NMPA) for the treatment of advanced solid tumours. 9MW2921 is developed by Mabwell's novel antibody-drug conjugate plateform IDDC™.

9MW2921 is an advanced antibody-drug conjugate (ADC) that has been developed using the IDDC™ (Interchain-Disulfide Drug Conjugate) platform specifically for the treatment of solid tumours.

9MW2921 exhibits specific binding to antigens present on the cell membrane surface of tumour cells. This specific binding is facilitated by the antibody component of the ADC, which recognises and attaches to the target antigens.

9MW2921 is a pharmaceutical compound that possesses several desirable characteristics. It is characterised by a stable structure, homogeneous composition, and high purity, making it suitable for industrial scale-up.

9MW2921 demonstrates an improved bystander killing effect. The bystander effect refers to the ability of a drug to induce cell death in neighbouring cells, even if they do not directly interact with the drug. By enhancing this effect, 9MW2921 can increase its overall efficacy by attacking not only the target cells but also the surrounding tumour microenvironment

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024